http://www.acc.org/Feed?clinicalTopicID=2db4bea0-4bbc-4fbd-b7b4-0e144f74ae32 Clinical Topic Feed: Nonstatins en /Latest-in-Cardiology/Journal-Scans/2026/07/20/14/38/GBD-2023 Nearly 90% of ischemic heart disease (IHD) deaths in 2023 in the U.S. were attributable to modifiable risk factors, led by high systolic blood pressure (SBP), dietary risks and high LDL-C, according to data from the Global Burden of Disease Study 2023 (GBD 2023), published July 15 in JAMA Cardiology. 1784735640000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/21/12/01/FDA-Update The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). 1784635560000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/01/12/47/eagles-eye-view-01jul2026 In this week’s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). 1782910140000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/01/01/Prioritizing-Health Earlier intervention and lower goals for LDL-C are key recommendations in the ACC/AHA Dyslipidemia Guideline, published in March – recognizing the risks of prolonged exposure to dyslipidemia leading to atherosclerotic cardiovascular disease (ASCVD). 1782907920000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/23/13/25/Combined-LDL-C-Lpa-and-hsCRP-Assessment Combined assessment of LDL-C, Lp(a) and hsCRP reflected independent pathways for identifying individuals of varied ethnicities at greater long-term risk of atherosclerotic cardiovascular disease (ASCVD), according to an analysis of the HELIUS cohort published June 24 in JACC. 1782413280000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/24/13/30/eagles-eye-view-24jun2026 In this week’s View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. 1782308100000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/17/16/52/CV-Risk-Factor Treatment of hypertension and hyperlipidemia was low among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, with less than half achieving blood pressure or glycemic control, and gaps in starting treatment were greatest among women, young adults and Hispanic adults. Furthermore, inadequate risk factor control was highest among those with the highest cardiovascular risk, according to research published June 17 in JACC. 1781716440000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/15/14/16/Implications-of-the-2026-Multisociety-Dyslipidemia-Guideline Lipid management remains a cornerstone of secondary prevention in atherosclerotic cardiovascular disease (ASCVD), with increasingly strong evidence supporting its central role across all vascular territories, including coronary, cerebrovascular, and peripheral arterial beds. 1781629980000 Articles and Stories https://www.jacc.org/doi/10.1016/j.jacc.2026.03.056 1781028000000 Guidelines /Latest-in-Cardiology/Journal-Scans/2026/06/08/17/44/First-Ever-Guideline-Addresses-CKM-Syndrome The new 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome is the first ever to address the "interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes)... 1781028000000 Articles and Stories